[LCID Study Number: 2018-053]
NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Lipsomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Lipsomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
The purpose of this study is to compare if it is safe and effective to add Atezolizumab to the usual chemotherapy treatment for ovarian or fallopian tube cancer, and to the usual chemotherapy for these cancers with bevacizumab. Atezolizumab has not been approved by the FDA. Researchers will look to see if either of these two treatment groups is potentially better than the other.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-9553